

3 Questions to....

...Miljana Bacevic from
Centre hospitalier
universitaire de Liège



PANBioRA

What has been most surprising for you related to your involvement in PANBioRA so far?

The most surprising to me was the fact that many patients are not only willing, but eager to dedicate their time and participate in a clinical study, where there are no direct, monetary or other, benefits for themselves (although, admittedly, no risks either in this case) to further advance medical research. I'm positively surprised to see how many of them truly understand that our society depends on mutual efforts and that every little step each of us can take will, hopefully, benefit thousands down the road. It is thanks to those people that we have achieved so much in the medical field so far, and that our health system and medical care continues to improve for the benefit of all.

From your point of view: What will be the biggest impact of PANBioRA?

I see PANBioRA as an optimal risk assessment tool that will be able to help us, clinicians, avoid many biomaterial-related complications and offer more personalised solutions to our patients.

This would further help significantly improve medical care and reduce health-related costs.



How would you describe PANBioRA in one sentence?

A risk assessment tool to help efficiently test new biomaterials and also to help compare available biomaterials and choose the best match for a given patient.

Learn more about Centre hospitalier universitaire de Liège and their involvement in PANBioRA!



Centre hospitalier universitaire de Liège



About Centre hospitalier universitaire de Liège (CHUL)

The [CHU of Liège](#) is the academic hospital linked to the University of Liège. Benefitting from a new ultramodern infrastructure and from the close interaction with the innovative [GIGA research Institute](#), doctors and scientists engaged in basic, translational, and clinical research are constantly guided by the will to transfer new knowledge and innovative therapeutic applications to patients as quickly and safely as possible, enabling optimized patient care. In PANBioRA the [Dental Biomaterials Research Unit](#) (d-BRU) in close collaboration with the [Department of Periodontology and Oral Surgery](#), particularly for clinical trials, as well as the Diabetes, Nutrition and Metabolic Disorders Unit (DNMD) are involved. All units are run by highly qualified and experienced teams of medical professionals working in the research field.

Role in PANBioRA:

CHUL's role is to help bringing PANBioRA testing to a clinical setting. CHUL will provide data and tissue samples from patients used for pre-clinical testing of the developed PANBioRA instrument in order to prove its efficacy in clinically relevant biomaterial-related risks. Two medical conditions have been chosen for this task: peri-implantitis related to dental implants and diabetic wound healing.

